BTG Pactual Global Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

BTG Pactual Global Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,796	Closed	-$346K	–	73
2018 Q3	$346K	Sell	1,796 -3,652	-67%	-$650K	0.14%	45
2018 Q2	$926K	Buy	5,448 +589	+12%	+$91.3K	0.27%	44
2018 Q1	$792K	Buy	4,859 +316	+7%	+$51.6K	0.21%	42
2017 Q4	$681K	Buy	4,543 +154	+4%	+$22.8K	0.25%	36
2017 Q3	$667K	Sell	4,389 -346	-7%	-$52.1K	0.21%	44
2017 Q2	$610K	Buy	4,735 +967	+26%	+$116K	0.18%	50
2017 Q1	$412K	Buy	+3,768	New	+$332K	0.15%	56

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BTG Pactual Global Asset Management's VRTX Position: Q4 2018 in Review

BTG Pactual Global Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 1,796 shares — an estimated $346K sold.

BTG Pactual Global Asset Management first reported a position in VRTX in Q1 2017 and held it in 7 quarters. The position peaked at $926K in Q2 2018. 706 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

BTG Pactual Global Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
BTG Pactual Global Asset Management sold 1,796 Vertex Pharmaceuticals shares in Q4 2018, an estimated $346K.
BTG Pactual Global Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 7 quarters.
BTG Pactual Global Asset Management's Vertex Pharmaceuticals position peaked at $926K in Q2 2018.
706 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on BTG Pactual Global Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.